Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 2/20 | 0.43 |
| ▸ | NOS3 | P29474 | 1/20 | 0.43 |
| ▸ | NOS1 | P29475 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 6/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.42 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.42 |
| ▸ | FAP | Q12884 | 1/20 | 0.42 |
| ▸ | PRCP | P42785 | 1/20 | 0.41 |
| ▸ | SCN4A | P35499 | 1/20 | 0.39 |
| ▸ | GLI1 | P08151 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL800609 | 1.00 | NOS2 (0.43) | NOS2NOS3NOS1DPP4DPP8 | |
| SCHEMBL14296385 | 1.00 | NOS2 (0.43) | NOS2NOS3NOS1DPP4DPP8 | |
| SCHEMBL801060 | 0.94 | DPP4 (0.38) | NOS2NOS3NOS1DPP4DPP8 | |
| SCHEMBL12611220 | 0.94 | DPP4 (0.38) | NOS2NOS3NOS1DPP4DPP8 | |
| SCHEMBL10001156 | 0.94 | DPP4 (0.38) | NOS2NOS3NOS1DPP4DPP8 | |
| SCHEMBL19844516 | 0.89 | NOS3 (0.37) | NOS2NOS3NOS1DPP4DPP8 | |
| SCHEMBL10037272 | 0.89 | NOS3 (0.37) | NOS2NOS3NOS1DPP4DPP8 | |
| SCHEMBL19844511 | 0.89 | NOS3 (0.37) | NOS2NOS3NOS1DPP4DPP8 | |
| SCHEMBL27859825 | 0.85 | NOS2 (0.42) | NOS2NOS3NOS1DPP4DPP8 | |
| SCHEMBL28793427 | 0.83 | NOS2 (0.41) | NOS2NOS3NOS1DPP4DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-20230331717-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2023-10-19 | — | — | US | disclosed |
| US-11786605-B2 | Site specific antibody-drug conjugates with peptide-containing linkers | MERSANA THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11723980-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| US-11723980-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| US-20230234912-A1 | NOVEL ANALOGS OF PTEROSTILBENE AMINO ACID BEARING CARBONATES FOR TREATING A NON-ALCOHOLIC FATTY LIVER DISEASE AND NONALCOHOLIC STEATOHEPATITIS | APICAL MOLECULAR BIOTECH CO., LTD. (TW) | 2023-07-27 | — | — | US | disclosed |
| US-20230234912-A1 | NOVEL ANALOGS OF PTEROSTILBENE AMINO ACID BEARING CARBONATES FOR TREATING A NON-ALCOHOLIC FATTY LIVER DISEASE AND NONALCOHOLIC STEATOHEPATITIS | APICAL MOLECULAR BIOTECH CO., LTD. (TW) | 2023-07-27 | — | — | US | disclosed |
| US-20230183326-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | ASANA BIOSCIENCES, LLC | 2023-06-15 | — | — | US | disclosed |
| US-11578074-B2 | Nitrogenous heterocyclic compound, preparation method, intermediate, composition, and application | Shanghai Pharmaceuticals Holding Cd., Ltd. (CN) | 2023-02-14 | — | — | US | disclosed |
| US-20090105122-A1 | Selective neuropeptide y2 receptor agonists | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-04-23 | — | — | US | disclosed |
| US-20090105122-A1 | Selective neuropeptide y2 receptor agonists | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-04-23 | — | — | US | disclosed |
| US-20090093417-A1 | Dual-acting antihypertensive agents | THERAVANCE, INC. | 2009-04-09 | — | — | US | disclosed |
| US-20090093417-A1 | Dual-acting antihypertensive agents | THERAVANCE, INC. | 2009-04-09 | — | — | US | disclosed |
| US-20090023228-A1 | Dual-acting Imidazole antihypertensive agents | THERAVANCE, INC. | 2009-01-22 | — | — | US | disclosed |
| US-20080318951-A1 | Dual-acting benzoimidazole antihypertensive agents | THERAVANCE, INC. | 2008-12-25 | — | — | US | disclosed |
| US-20080317744-A1 | Indole and Benzimidazole Derivatives | CHIRON CORPORATION (US) | 2008-12-25 | — | — | US | disclosed |
| US-20080317744-A1 | Indole and Benzimidazole Derivatives | CHIRON CORPORATION (US) | 2008-12-25 | — | — | US | disclosed |
| US-20080269305-A1 | R)-N-{2-Butyl-3-[2'-(2H-tetrazol-5-yl)biphenyl-4-ylmethyl]-3H-imidazol-4-ylmethyl}-2-(2-hydroxycarbamoyl-3-phenyl-propionylamino)succinamic Acid; AT1 receptor antagonist and neprilysin (NEP) enzyme inhibition activity; hypertension, heart failure | THERAVANCE, INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080188533-A1 | 2-Mercaptomethyl-4-methylpentanoic Acid (2-Butyryl-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]aminoethyl)amide | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093417-A1 | Dual-acting antihypertensive agents | AGTR1, REN, AGTR2 | NOS2 1464/4885NOS3 510/4885NOS1 1334/4885 |
| US-20080269305-A1 | R)-N-{2-Butyl-3-[2'-(2H-tetrazol-5-yl)biphenyl-4-ylmethyl]-3H-imidazol-4-ylmethyl}-2-(2-hydroxycarbamoyl-3-phenyl-propionylamino)succinamic Acid; AT1 receptor antagonist and neprilysin (NEP) enzyme inhibition activity; hypertension, heart failure | AGTR2, REN, AGTR1 | NOS2 2728/4885NOS3 2131/4885NOS1 3096/4885 |
| US-20230183326-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, STAMBP, TSPO | NOS2 4138/4885NOS3 3732/4885NOS1 4135/4885 |
| US-20230331717-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TP53, KRAS, HRAS | NOS2 4449/4885NOS3 4134/4885NOS1 4666/4885 |
| US-11723980-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | NOS2 3629/4885NOS3 3425/4885NOS1 3662/4885 |
| US-20230234912-A1 | NOVEL ANALOGS OF PTEROSTILBENE AMINO ACID BEARING CARBONATES FOR TREATING A NON-ALCOHOLIC FATTY LIVER DISEASE AND NONALCOHOLIC STEATOHEPATITIS | FABP1, GLS2, SLC1A5 | NOS2 200/4885NOS3 438/4885NOS1 107/4885 |
| US-20090105122-A1 | Selective neuropeptide y2 receptor agonists | NPY2R, NPY1R, NPY4R | NOS2 1536/4885NOS3 1503/4885NOS1 2811/4885 |
| US-20090023228-A1 | Dual-acting Imidazole antihypertensive agents | AGTR1, AGTR2, REN | NOS2 258/4885NOS3 134/4885NOS1 370/4885 |
| US-11578074-B2 | Nitrogenous heterocyclic compound, preparation method, intermediate, composition, and application | ERBB2, EGFR, ERBB4 | NOS2 531/4885NOS3 1086/4885NOS1 598/4885 |
| US-11786605-B2 | Site specific antibody-drug conjugates with peptide-containing linkers | CD2BP2, DNPEP, LNPEP | NOS2 4832/4885NOS3 4593/4885NOS1 4818/4885 |
| US-20080188533-A1 | 2-Mercaptomethyl-4-methylpentanoic Acid (2-Butyryl-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]aminoethyl)amide | MME, AGTR1, AGTR2 | NOS2 3926/4885NOS3 3295/4885NOS1 3383/4885 |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | NOS2 3629/4885NOS3 3425/4885NOS1 3662/4885 |
| US-20080317744-A1 | Indole and Benzimidazole Derivatives | IDO1, IDO2, AADAC | NOS2 356/4885NOS3 803/4885NOS1 1173/4885 |
| US-20080318951-A1 | Dual-acting benzoimidazole antihypertensive agents | AGTR1, REN, AGTR2 | NOS2 739/4885NOS3 271/4885NOS1 951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.